Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial

Table 4 Nab-paclitaxel-containing regimens for metastatic breast cancer

Study	Regimen	Study design and setting	Number of patients	Overall response rate	Median time to progression/progression-free survival (months)	Median overall survival (months)
Our study	Nab-paclitaxel 125 mg/m²+ GEM 800 mg/m², days 1, 8, 15, q4w	Phase II,all lines	84	52.40%	7.9	25.8
Gradishar et al. [3]	Nab-paclitaxel 260 mg/m²,q3w	Phase III,all lines	229	33%	23.0(weeks)	NR
Gradishar et al. [3]	Paclitaxel 175 mg/m2,q3w	Phase III,all lines	225	19%	16.9(weeks)	NR
Gradishar et al. [14]	Nab-paclitaxel 300 mg/m²,q3w	Phase II, first-line	76	37%	11	27.7
	Nab-paclitaxel 100 mg/m² weekly, days 1, 8, 15, q4w		76	45%	12.8	22.2
	Nab-paclitaxel 150 mg/m² weekly, days 1, 8, 15, q4w		74	49%	12.9	33.8
	Docetaxel 100 mg/m²,q3w		74	35%	7.5	26.6
Roy et al. [6]	Nab-paclitaxel 125 mg/m² weekly, days 1,8,q3w + GEM 1000 mg/m² weekly, days 1,8,q3w	Phase II, first-line	50	50%	7.9	NR
Lobo et al. [7]	Nab-paclitaxel 150 mg/m2 + GEM 1500 mg/m2 + bevacizumab 10 mg/kg,day 1,15,q4w	Phase II, first-line, TNBC	30	75.90%	10.4	NR
Sun et al. [13]	Nab-paclitaxel 125 mg/m2, days 1, 8, 15+ DDP 75 mg/m2, q4w	Phase II,all lines	73	67.10%	9.8	26.9

Abbreviations: q3w: every 3 weeks, GEM: gemcitabine, DDP: cisplatin, TNBC: tri-negative breast cancer

ISSN: 1471-2407